A newly developed antibody targeting a signalling pathway that is frequently active in solid tumors has shown encouraging signs of efficacy in its first trial in humans, researchers report.
A newly developed antibody targeting a signalling pathway that is frequently active in solid tumors has shown encouraging signs of efficacy in its first trial in humans, researchers report.